Other Transfusion Projects & People

 Some other projects being undertaken by TORC partnership organisations:

  • Myeloma and Related Diseases Registry (MRDR)
    Although myeloma accounts for only 1.2% of all cancers, it was one of the ten most common cancers recorded as the primary reason for hospitalisation in Australia in 2007-2009. There is substantial variation in the therapy provided to patients with myeloma, including the choice of induction therapy, choice of therapy for primary refractory disease and relapsed disease and the use of maintenance therapy. The Myeloma and Related Diseases Registry (www.mrdr.net.au) aims to better define the incidence, natural history, clinical outcomes and optimal management of these patients with myeloma or a related disease as well as provide information on a range of therapeutic strategies and explore factors influencing clinical outcomes. Click here to access the MRDR database. 
  • VTE Cohort Study
    Although VTE is quite a common illness, there is still a lot we don’t know about its cause or how to best treat it. From 2011, some key information about people who are being treated for Venous Thromboembolism (VTE) is being collected by the VTE Cohort Study at the Department of Epidemiology and Preventive Medicine, Monash University. The purpose of the VTE Cohort Study is to help doctors and nurses provide the best possible care to people with VTE and assist researchers in understanding the causes and outcomes of people with this illness. For further information click here, for access to the VTE Registry database click here.
  • Haemostasis Registry - click here for Project Final Report
    The Haemostasis Registry was established in February 2005 at the Department of Epidemiology and Preventive medicine. The purpose of this registry is to gain information on safety, efficacy and appropriateness of use and dosages of recombinant activated factor VII (rFVIIa, NovoSeven) where it is used for non-haemophiliac patients. Establishment of a register will provide valuable observational data including efficacy, adverse events, effective dosage and cost-effectiveness. This data will be of substantial value in the development of prospective trials. The registry is supported by an educational grant from Novo Nordisk.  For further information click here.
  • WBIT Project - Reducing Harm in Blood Transfusion
    Investigating the Human Factors behind ‘Wrong Blood in Tube’ (WBIT) events in the Emergency Department: A literature and gap analysis of current best practice guidelines surrounding WBIT both nationally and internationally.

TORC to our friends: